Choreo LLC Acquires New Position in Affimed (NASDAQ:AFMD)

Choreo LLC acquired a new stake in Affimed (NASDAQ:AFMD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned 0.07% of Affimed as of its most recent SEC filing.

Separately, BNP Paribas Financial Markets lifted its position in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the period. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Price Performance

Shares of Affimed stock opened at $3.69 on Friday. Affimed has a 12-month low of $2.23 and a 12-month high of $8.95. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $4.41 and a two-hundred day moving average of $5.11.

Analyst Upgrades and Downgrades

AFMD has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. Finally, Laidlaw increased their target price on shares of Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.50.

Affimed Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.